{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016130","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.851035+00:00","generated_at":"2026-06-24T01:57:23.865300+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kodiak Sciences Q2 net loss $90.6M; BEACON Phase 3 RVO study meets endpoint","bullets":["Net loss of $90.6M ($1.74/share) vs $55.9M ($1.08/share) in Q2 2021 driven by higher R&D and stock-based comp.","Cash and equivalents $597.9M at quarter-end, down from prior quarter but sufficient for operations.","BEACON study in RVO met primary endpoint: tarcocimab every 8 weeks non-inferior to aflibercept monthly.","Phase 3 DME studies GLEAM/GLIMMER and wet AMD study DAYLIGHT fully enrolled; topline data expected mid-2023.","Plans to file single BLA for tarcocimab across all indications if Phase 3 data are positive."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016130","json":"https://secwatch.observer/filing/0000950170-22-016130.json","markdown":"https://secwatch.observer/filing/0000950170-22-016130.md","text":"https://secwatch.observer/filing/0000950170-22-016130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022016130/0000950170-22-016130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022016130/kod-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:57:23.865300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}